OBJECTIVE: In the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel concomitantly and as maintenance for women with newly-diagnosed advanced ovarian cancer significantly improved progression-free survival (PFS) versus chemotherapy alone. Here we present exploratory analyses by paclitaxel dosing schedule and germline BRCA (gBRCA) status. METHODS: Women with untreated ovarian carcinoma were randomized (1:1:1) to: veliparib during chemotherapy and maintenance (veliparib-throughout), veliparib during chemotherapy followed by placebo maintenance (veliparib-combination only), or placebo during chemotherapy and maintenance (control). Chemotherapy included carboplatin plus dose-dense (DD; weekly) or every-3-week (Q3W...
Background: Standard of care first line chemotherapy for epithelial ovarian cancer (EOC) is carbopla...
Purpose To analyze the effect of different doses of paclitaxel with fixed doses of carboplatin in th...
The objective of this study was to compare the safety and efficacy of carboplatin plus epirubicin an...
OBJECTIVE: In the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel ...
ObjectiveIn the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel co...
Objective: In the Phase 3 VELIA trial (NCT02470585), PARP inhibitor (PARPi) veliparib was combined w...
Objective: In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherap...
BACKGROUND: Carboplatin plus paclitaxel administered every 3 weeks is standard first-line chemothera...
BACKGROUND: Epithelial ovarian cancer is the sixth most common cancer worldwide: 295,414 new cases w...
BACKGROUND: BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP...
Objective To systematically evaluate the efficacy and safety of paclitaxel and carboplatin dose-den...
IMPORTANCE: Patients with platinum-resistant or refractory ovarian high-grade serous carcinoma (PR-H...
Background Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a no...
Background Carboplatin and paclitaxel administered every three weeks is standard-of-care first-line ...
PURPOSE: To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progr...
Background: Standard of care first line chemotherapy for epithelial ovarian cancer (EOC) is carbopla...
Purpose To analyze the effect of different doses of paclitaxel with fixed doses of carboplatin in th...
The objective of this study was to compare the safety and efficacy of carboplatin plus epirubicin an...
OBJECTIVE: In the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel ...
ObjectiveIn the Phase 3 VELIA trial (NCT02470585), veliparib added to carboplatin plus paclitaxel co...
Objective: In the Phase 3 VELIA trial (NCT02470585), PARP inhibitor (PARPi) veliparib was combined w...
Objective: In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherap...
BACKGROUND: Carboplatin plus paclitaxel administered every 3 weeks is standard first-line chemothera...
BACKGROUND: Epithelial ovarian cancer is the sixth most common cancer worldwide: 295,414 new cases w...
BACKGROUND: BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP...
Objective To systematically evaluate the efficacy and safety of paclitaxel and carboplatin dose-den...
IMPORTANCE: Patients with platinum-resistant or refractory ovarian high-grade serous carcinoma (PR-H...
Background Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a no...
Background Carboplatin and paclitaxel administered every three weeks is standard-of-care first-line ...
PURPOSE: To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progr...
Background: Standard of care first line chemotherapy for epithelial ovarian cancer (EOC) is carbopla...
Purpose To analyze the effect of different doses of paclitaxel with fixed doses of carboplatin in th...
The objective of this study was to compare the safety and efficacy of carboplatin plus epirubicin an...